Myriad Genetics (MYGN) Beats Estimates
August 11, 2010 at 12:15 PM EDT
Myriad Genetics Inc. (MYGN) recorded an EPS of 54 cents in the fourth quarter of 2010, surpassing the Zacks Consensus Estimate of 33 cents and 24 cents in the year-ago period. For the full year 2010, the company recorded 79% growth in EPS to $1.54, beating the Zacks Consensus Estimate of $1.32 per share. Results in [...]